Across the U.S. and the UK, health agencies have been tracking newer COVID lineages including NB.1.8.1, often referred to in media coverage as “Nimbus,” and XFG, which has been called “Stratus.” One important correction: the strain commonly linked to the “Stratus” nickname is XFG, not XFB. Both XFG and NB.1.8.1 have been identified as variants under monitoring, and global health authorities say their growth reflects the virus’s continuing ability to evolve and spread efficiently.
The numbers behind that spread have drawn attention, even without the kind of panic seen in earlier years. In England, UKHSA surveillance previously recorded hospital-setting PCR positivity nearing 8% in the oldest age group during a 2025 rise, while more recent 2026 reporting shows lower levels overall, a reminder that activity can shift over time. In the United States, CDC wastewater monitoring continues to track changing variant proportions nationally, which helps show transmission trends even when many infections are never formally tested.
For many people, the experience can still feel rougher than expected. Reports tied to NB.1.8.1 and XFG have described familiar COVID symptoms such as sore throat, fatigue, headache, congestion, cough, and in some cases hoarseness or an especially painful throat. Even so, major public-health sources have not said these variants cause more severe disease overall than other recent strains; the concern is more about how widely they can circulate than about a dramatic change in severity.
What health leaders continue to recommend is steady, practical caution rather than alarm. WHO says the added public-health risk from NB.1.8.1 and XFG is currently considered low, and available evidence indicates vaccines are still expected to protect against severe disease. That is why the guidance remains familiar: stay home when sick, consider masking in crowded indoor settings if you are at higher risk or protecting someone vulnerable, and test when symptoms begin so you can make informed choices early.